Biohit Oyj - Company Announcement

Changes to Biohit Oyj’s management

MD, Ph.D., FIAC Kari Syrjänen (b. 1948) has been appointed as Chief Medical
Director and a member of the management team in Biohit Oyj. Syrjänen has been
operating for more than 40 years in various universities and hospitals in
Finland and abroad, among others as professor of pathology and chairman of
department, dean of the faculty, as well as a visiting professor at several
foreign universities and research institutes. 



Additional information:
CEO Semi Korpela, Biohit Oyj
Tel. +358 9 773 861
semi.korpela@biohit.fi
www.biohithealtcare.com



Biohit Oyj in brief

Biohit Oyj is a Finnish biotechnology company operating globally that was
established in 1988. Biohit's mission is “Innovating for Health” and “Cancer
Prevention”. The purpose of the company is to take social responsibility and
produce innovation, new technologies and analysis systems for use in medicine,
research institutions and industry, helping to promote research and diagnostics
and to improve the quality of life of people by means of preventing disease,
human suffering and financial loss. We are committed to responsibility and it
is our duty to innovate and develop the marketing and availability of our
products and services. Biohit is headquartered in Helsinki and its subsidiaries
are located China and UK. Since 1999, Biohit's Series B shares (BIOBV) have
been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector.